OverviewSuggest Edit

Gamida Cell develops stem cell therapy technologies and products for the treatment of blood cancers, autoimmune and metabolic diseases. The Company’s scientists have developed a broad platform technology to expand functional cells in culture to create life-saving cures for blood cancers such as leukemia and lymphoma and rare genetic diseases such as sickle cell disease.

TypePublic
Founded1998
HQBoston, MA, US
Websitegamida-cell.com

Latest Updates

Employees (est.) (Feb 2019)52
Share Price (Dec 2021)$2.5
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Gamida Cell

Julian Adams

Julian Adams

Chief Executive Officer, Director
Josh Hamermesh

Josh Hamermesh

Chief Business Officer
Michele Korfin

Michele Korfin

Chief Operating and Chief Commercial Officer
Ronit Simantov

Ronit Simantov

Chief Medical Officer
Shai Lankry

Shai Lankry

Chief Financial Officer
Naftali Brikashvili

Naftali Brikashvili

Senior Vice President, Finance and Operations
Show more

Gamida Cell Office Locations

Gamida Cell has offices in Boston and Jerusalem
Boston, MA, US (HQ)
673 Boylston St 4th Floor
Show all (2)

Gamida Cell Financials and Metrics

Gamida Cell Revenue

USD

Market capitalization (31-Dec-2021)

149.3m

Closing stock price (31-Dec-2021)

2.5

Cash (31-Dec-2020)

127.2m
Gamida Cell's current market capitalization is $149.3 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

4.6m4.5m

R&D expense

19.1m15.0m

Operating expense total

23.7m19.5m

EBIT

(23.7m)(19.5m)
Quarterly
USDQ2, 2017Q2, 2018

General and administrative expense

747.0k2.9m

R&D expense

2.7m7.0m

Operating expense total

3.4m9.9m

EBIT

(9.1m)(16.6m)
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

18.1m21.3m40.3m41.8m127.2m

Prepaid Expenses

377.0k2.5m

Current Assets

18.4m43.6m62.2m56.7m130.0m

PP&E

700.0k940.0k2.3m6.3m18.2m
Quarterly
USDQ2, 2017Q2, 2018

Cash

9.8m19.0m

Prepaid Expenses

1.7m1.5m

Current Assets

11.5m30.2m

PP&E

840.0k1.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(22.7m)(19.0m)(52.9m)(34.4m)(72.7m)

Depreciation and Amortization

124.0k162.0k

Accounts Payable

297.0k1.5m

Cash From Operating Activities

(12.6m)(17.8m)(26.4m)(37.9m)(48.6m)
Quarterly
USDQ2, 2017Q2, 2018

Net Income

(9.3m)(20.5m)

Depreciation and Amortization

68.0k97.0k

Accounts Payable

100.0k(1.2m)

Cash From Operating Activities

(8.0m)(13.3m)
USDFY, 2016

Financial Leverage

1.7 x
Show all financial metrics

Gamida Cell Operating Metrics

Q3, 2018

Patients Reached

120
Show all operating metrics

Gamida Cell Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Gamida Cell Online and Social Media Presence

Embed Graph

Gamida Cell News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gamida Cell Ltd. - GMDA

NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gamida Cell Ltd. (“Gamida” or the “Company”) (NASDAQ: GMDA).   Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Gamida Cell Ltd. - GMDA

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gamida Cell Ltd. ("Gamida" or the "Company") (NASDAQ: GMDA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...

Thinking about buying stock in Newtek Business Services, Fulcrum Therapeutics, Gamida Cell, PubMatic, or Falcon Capital Acquisition?

NEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEWT, FULC, GMDA, PUBM, and SHCR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Global Stem Cell Therapy Market Report 2021-2030 Featuring Anterogen, JCR Pharma, Medipost, Osiris Therapeutics, Pharmicell, Astellas Pharma, Cellectis, Celyad, Novadip Biosciences, and Gamida Cell

Dublin, May 17, 2021 (GLOBE NEWSWIRE) -- The "Stem Cell Therapy Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering. Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 provides the strategists, marke…

Thinking about buying stock in Gamida Cell, Co-Diagnostics, T2 Biosystems, FSD Pharma, or Allena Pharmaceuticals?

NEW YORK, Feb. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMDA, CODX, TTOO, HUGE, and ALNA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Israeli biotech drug developer Gamida Cell files for IPO

Israeli biotech drug developer Gamida Cell Ltd. said late Friday it is going public to help fund clinical trials and build out a manufacturing plant, according to a filing with the Securities and Exchange Commission. The Jerusalem-based company plans to raise up to $69 million in an initial public …

Gamida Cell Frequently Asked Questions

  • When was Gamida Cell founded?

    Gamida Cell was founded in 1998.

  • Who are Gamida Cell key executives?

    Gamida Cell's key executives are Julian Adams, Josh Hamermesh and Michele Korfin.

  • How many employees does Gamida Cell have?

    Gamida Cell has 52 employees.

  • Who are Gamida Cell competitors?

    Competitors of Gamida Cell include Presage, Xintela and Olaris.

  • Where is Gamida Cell headquarters?

    Gamida Cell headquarters is located at 673 Boylston St 4th Floor, Boston.

  • Where are Gamida Cell offices?

    Gamida Cell has offices in Boston and Jerusalem.

  • How many offices does Gamida Cell have?

    Gamida Cell has 2 offices.